Typhoid Fever Clinical Trial
Official title:
Treatment of 21st Century Typhoid Fever in Children;Open Label Mono vs Combination Drug Therapy
This study evaluates whether XDR Typhoid fever in children can be effectively treated with monotherapy (meropenum alone), or a combination (meropenum and azithromycin).
Complicated XDR Enteric fever is a very serious systemic disease, caused by an extremely resistant mutant strain of Salmonella Typhi ( the H58 S. Typhi superbug,) that as the name suggests is resistant to not only the first but also the second tier drugs conventionally used for treatment of the same. And as such, warrants immediate antibiotic therapy, but in view of the extended antimicrobial resistance the treatment options are limited to only two effective drugs viz Carbepenem and Azithromycin, as per culture sensitivity. So far, in the absence of universal standardized treatment protocols for XDR complicated typhoid fever in children, random use of either one or both in combination is the current practice. However, keeping antibiotic stewardship in mind, it is imperative to ascertain whether meropenum alone is effective or should be combined with azithromycin in the treatment of this serious disease. Our study therefore compares the efficacy of monotherapy with meropenum or combination with azithromycin based on clinical and microbiologic remission, shortened hospital stay and less chances of relapse in order to then formulate a standardized protocol to treat complicated XDR typhoid in children thus preventing yet further antimicrobial resistance. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04830371 -
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
| Completed |
NCT02324751 -
Vaccines Against Salmonella Typhi
|
Phase 2 | |
| Completed |
NCT01421693 -
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
|
Phase 4 | |
| Completed |
NCT05579821 -
Evaluation Study of DPP® Typhoid Assay
|
||
| Completed |
NCT02947295 -
Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
|
||
| Completed |
NCT01405521 -
Understanding Typhoid Disease After Vaccination
|
Phase 2 | |
| Completed |
NCT00386789 -
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
|
N/A | |
| Completed |
NCT04801602 -
Commercial Typhoid Tests Validation Trial
|
||
| Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
| Completed |
NCT01437267 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
|
Phase 2 | |
| Completed |
NCT01438996 -
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
|
Phase 2 | |
| Completed |
NCT01193907 -
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
|
Phase 2 | |
| Recruiting |
NCT04349826 -
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
|
Phase 4 | |
| Completed |
NCT01608815 -
Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
|
Phase 3 | |
| Completed |
NCT01123941 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
|
Phase 1 | |
| Recruiting |
NCT05500482 -
Vellore Typhoid Vaccine Impact Trial
|
Phase 4 | |
| Completed |
NCT03926455 -
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
|
Phase 1 | |
| Completed |
NCT01229176 -
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
|
Phase 2 | |
| Completed |
NCT03956524 -
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
|
Phase 1 |